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ABSTRACT  
Background: Previous studies have reported an association between weight increase and excess 
lung function decline in young adults followed for short periods. We aimed to estimate lung 
function trajectories during adulthood according to 20-years weight change profiles, using data 
from the population-based European Community Respiratory Health Survey (ECRHS). 
Methods: We included 3,673 participants recruited at age 20-44 years with repeated 
measurements of weight and lung function (FVC, FEV1) in three study waves (1991-93, 1999-
2003, 2010-14) until they were 39-67 years. We classified subjects into weight change profiles 
according to baseline BMI categories and weight change over 20 years. We estimated 
trajectories of lung function over time as a function of weight change profiles using population-
averaged generalised estimating equations. 
Results: In individuals with normal BMI, overweight and obesity at baseline, moderate (0.25–
1kg/year) and high weight gain (>1kg/year) during follow-up were associated with accelerated 
FVC and FEV1 declines. Compared to participants with baseline normal BMI and stable weight 
(±0.25kg/year), obese with high weight gain during follow-up had -1,011 ml [95%CI: -1,259 to 
-763] lower estimated FVC at 65 years, despite similar estimated FVC levels at 25 years. Obese 
individuals at baseline who lost weight (<-0.25kg/year) exhibited an attenuation of FVC and 
FEV1 declines. We found no association between weight change profiles and FEV1/FVC 
decline.  
Conclusion: Moderate and high weight gain over 20-years was associated with accelerated lung 
function decline, while weight loss was related to its attenuation. Control of weight gain is 
important for maintaining good lung function in adult life. 
 
Abstract word count: 250 
Keywords: adults, BMI, lung function, obesity, weight change, epidemiology 
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KEY MESSAGES 
What is the key question? 
Is weight change over a 20-year period associated with lung function trajectories in adult life? 
What is the bottom line? 
Moderate and high weight gain over a 20-year period was associated with accelerated FVC and 
FEV1 decline, while weight loss was related to its attenuation. 
Why read on?  
This study, which is based on data collected as part of the multicentre prospective ECRHS 
study, reinforce the public health message that overweight and obesity have deleterious effects 
on respiratory health. However, these negative effects can be reversed by weight loss even later 
in adult life.   
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BACKGROUND 
Lung function is a significant predictor of future morbidity and mortality in the general 
population.[1] Maintaining good lung function across adult life is important to prevent chronic 
respiratory diseases, which nowadays represent a serious public health problem around the 
world.[2] There is consistent evidence showing that overweight, obesity, and weight gain in 
adulthood are detrimental to lung function, as described by the forced vital capacity (FVC) 
and/or forced expiratory volume in one second (FEV1). Previous population-based and 
occupational cohort studies have shown that excessive weight gain in adulthood is associated 
with lower lung function levels and with an increased rate of lung function decline 
independently of age and smoking status.[3–8] Another longitudinal study in healthy young 
adults (age range at baseline: 18-30 years) showed that lung function was lower both with 
higher baseline body mass index (BMI) and with increasing BMI over a ten-year period.[9] 
Similarly, a population-based study of young adults (mean age at baseline: 41 years) analyzing 
the effects of changes in obesity status on lung function found that remaining or becoming 
obese accelerated lung function decline over an eight-year follow-up, while becoming non-
obese was related to its attenuation.[10]  
All these previous studies have had relatively short follow-up periods (up to ten years) and most 
investigated this link only up to 50 years of age. This precludes a more comprehensive 
understanding of the role of weight change on lung function during adulthood and older life and 
supports the need for further studies with longer follow-up periods extending into late adult life. 
Understanding the effects of weight changes on lung function during adult life is of utmost 
importance given the epidemic levels of overweight and obesity globally.[11] 
The European Community Respiratory Health Survey (ECRHS) is a large multicentre 
population-based study with available measures of weight, height and lung function at three 
time points over a twenty-year period, as well as detailed information of sociodemographic and 
lifestyle factors from adults living across Europe and Australia. [12–14] Under the framework 
of the Ageing Lungs in European Cohorts (ALEC) consortium (www.alecstudy.org), we aimed 
to assess the lung function trajectories of adults of the ECRHS study according to different 
weight change profiles that combined BMI at baseline and weight change over a twenty-year 
period.  
METHODS 
Study population 
The ECRHS started in 1991–1993 (ECRHS I), when over 18,000 young adults aged 20-44 years 
were randomly recruited from available population-based registers (population-based arm), with 
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an oversampling of asthmatics (symptomatic arm). Participants were followed-up in 1999-2003 
(ECRHS II) and 2010-2014 (ECRHS III), when they were aged 27-57 and 39-67 years, 
respectively.  More details of the study design are available elsewhere.[12–14] In this analysis, 
we included participants who had weight at ECRHS I and III, and lung function and base 
covariates (sex, age, height and smoking status) at all  three surveys (3,673 participants of 26 
centres in 12 countries) (Figure S1).  
Ethical approval was obtained from the ethics committees of all participating institutions and all 
participants provided informed written consent. 
 
Lung function 
Lung function was measured by spirometry at ECRHS I, II and III. Centres used different 
spirometers at ECRHS I and II, but almost all centres used the same spirometer at ECRHS III 
(Table S1).  In the three examinations, forced vital capacity (FVC) and forced expiratory 
volume in 1 second (FEV1), repeatable to 150 mL from at least two of a maximum of five 
correct manoeuvres that met the American Thoracic Society and European Respiratory Society 
recommendations,[15] were used as the primary outcomes. The FEV1/FVC ratio was also 
analysed. In the present analysis, we used lung function measurements collected pre-
bronchodilator. We also calculated lung function standard deviation scores (z-scores) using the 
Global Lung Initiative (GLI) equation references,[16] and used these variables as secondary 
outcomes.  
 
Weight change profiles 
BMI was calculated by dividing measured weight (kg) by measured height (m) squared. We 
defined categories of BMI at ECRHS I (baseline) as ‘underweight’ (BMI<20 kg/m2), ‘normal-
weight’ (20 kg/m2 ≤ BMI< 25 kg/m2), ‘overweight’ (25 kg/m2 ≤ BMI < 30 kg/m2) and ‘obese’ 
(BMI ≥ 30 kg/m2), as in previous ECRHS studies.[8] We computed weight change during 
follow-up as the difference between weight measured at ECRHS III and ECRHS I divided by 
the total time of follow-up (in years) and categorised it into stable weight, weight loss and 
weight gain. Since there are no standard references for weight change in adults, we used similar 
weight change categories as in a recent longitudinal long term population-based study:[17] 
‘weight loss’ (<-0.25 kg/year), ‘stable weight (±0.25kg/year)’, ‘moderate weight gain’ (>0.25 to 
≤1 kg/year) and ‘high weight gain’ (>1 kg/year). We combined baseline BMI categories with 
weight change categories to classify participants in weight change profiles. This combined 
variable was used as the main exposure variable in the analysis.  
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Other relevant variables 
Sociodemographic and other health data were collected using questionnaires. These included 
sex, age, age completed full-time education (<17 years; 17–20 years; >20 years), smoking status 
(never smoker; ex-smoker, current smoker), second-hand smoke exposure (yes; no) and asthma 
(yes; no). Current asthma was defined as having reported physician-diagnosed asthma and at 
least one of the following: asthma-like symptoms (wheeze, nocturnal chest tightness, attacks of 
breathlessness after activity/at rest/at night-time), asthma attacks, use of inhaled/oral medicines 
for breathing problems (in the last 12 months), or current use of inhalers, aerosols or tablets for 
asthma. Leisure-time vigorous physical activity was assessed at ECRHS II by asking 
participants how often and for how many hours per week they usually exercised so much that 
they got out of breath or sweaty. Participants were categorised as being active if they exercised 
with a frequency of two or more times a week and with duration of about 1 hour a week or 
more, and non-active otherwise.[18] Finally, at ECRHS II participants reported if they presented 
any of the following long-term limiting illness: hypertension, heart disease, diabetes, cancer or 
stroke.  
 
Statistical analysis 
We used population-averaged generalised estimating equations (GEE) to estimate lung function 
trajectories from age 20 to 67 years (the full age range of the study sample) as a function of 
weight change profiles. Prior to stratifying models by weight change profiles, we tested the 
interaction between age, BMI at baseline and weight change, and we found that it was 
statistically significant for all lung function parameters (p-value <0.01 for all models). All GEE 
models had the individuals as the clustering factor (to account for repeated lung function 
measurements at ECRHS I, II and III) and an unstructured within-cluster correlation. GEE 
models had FVC, FEV1 or FEV1/FVC as the outcome variables. Interaction terms between age 
(or age squared) and weight change profiles were entered to allow for different trajectories of 
lung function with aging across weight change profiles. We entered sex as a fixed covariate and 
height, age, age squared, smoking status, current asthma and spirometer type as time-specific 
covariates. We also included an interaction term between smoking status and age (to account for 
a faster decline over time in smokers). We centred continuous variables at the mean (over the 
data from the three examinations) before modelling. Adjusted lung function over age was 
calculated by setting continuous and categorical variables equal to the mean and proportion, 
respectively (calculated over the study sample).   
In a secondary analysis we repeated the models using lung function z-scores instead of absolute 
lung function values. To assess whether estimated lung function trajectories differed by sex we 
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tested for sex interactions (by including an interaction term between sex and weight change 
profiles) and we stratified final models by sex. We performed several sensitivity analyses to 
assess the robustness of the estimated lung function trajectories to various assumptions 
regarding confounding, change of spirometry devices or weight change categorisation (see the 
online supplement).  
All analyses were conducted following a complete case approach in Stata/SE 14.0 (StataCorp, 
College Station, TX, USA). 
RESULTS 
Characteristics of the study sample 
Compared with those not included in the present analysis (n=12,909), individuals who were 
included were slightly older, less likely to be current-smokers, be exposed to second hand 
smoke and had higher educational levels at ECRHS I, but they did not differ in terms of weight, 
BMI and lung function (Table S2). Table 1 shows the main characteristics of the study sample 
(n=3,673). Mean (SD) age of the study sample was 34.3 (7.1) years at baseline and 54.3 (7.1) 
years at the last follow-up. Approximately half of the study sample were women (53.3%) and 
40% completed full-time education when they were 20 years of age or older.  
At baseline, 12% of the sample was underweight, 57% normal weight, 24% overweight and 6% 
obese. During follow-up almost 4% of the sample lost weight, 34% had stable weight, 53% had 
a moderate weight gain and 9% had high weight gain. Table 2 shows descriptive statistics of the 
sixteen weight change profiles identified. Almost 20% of the sample was classified in the 
weight change profile with baseline normal BMI and stable weight during follow-up. Out of the 
groups who lost weight during follow-up, obese participants at baseline were those who lost 
more weight over time (median: -0.6 kg/year, P25-P75: -0.9; -0.4), while among those who 
experienced a moderate increase in weight, median weight gain was the same in the different 
categories of baseline BMI. Among those with high weight gain during follow-up, overweight 
and obese participants at baseline were those who gained more weight. Underweight 
participants who lost weight or had a high weight gain represented less than one percent of the 
study sample and therefore were excluded from further analyses.  
Associations between weight change profiles and lung function trajectories  
To facilitate interpretation of results, the estimated trajectories of lung function by weight 
change profiles are presented separately for normal BMI, overweight and obese categories at 
baseline (Figures 1 to 3). Among adults with baseline normal BMI, overweight and obesity, 
those with moderate and high weight gain during follow-up exhibited significant steeper FVC 
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decline than those with stable weight (Panels A, B and C in Figure 1). Estimated differences in 
FVC at 25 and 65 years by weight change profiles (Table S3) show that in comparison with 
participants with baseline normal BMI and stable weight, baseline overweight and obese 
participants with high weight gain had lower estimated FVC at 65 years (-677 ml [95%CI: -841 
to -512]; p<0.001 and -1,011 ml [-1,259 to -763]; p<0.001, respectively) despite similar 
estimated FVC levels at age 25 (Table S3).  
In contrast to weight gain, obese (but not overweight or normal BMI) adults at baseline who lost 
weight during follow-up exhibited an attenuation of FVC decline (Panel C in Figure 1). We 
estimated that, at age 25 years, obese participants had lower FVC levels than normal BMI 
participants. However, obese who lost weight during follow-up were estimated to have not 
significantly different FVC values at age 65 years than participants with baseline normal BMI 
and stable weight (Table S3).  
Supplementary Figure S2 shows lung function trajectories for subjects with baseline 
underweight. In young adulthood, participants with baseline underweight had lower estimated 
FVC values than baseline normal BMI participants (Figure S2). However, baseline underweight 
with stable weight during follow-up were estimated to have very similar FVC values at age 65 
than participants with baseline normal BMI and stable weight.  
We found very similar results for estimated FEV1 trajectories (Figure 2, Figure S2 and Table 
S4). We found no evidence that FEV1/FVC ratio trajectories were different by weight change 
profiles, except for two groups. Subjects with baseline underweight who had stable weight or 
moderate weight gain showed a steeper decline of FEV1/FVC ratio than participants with 
baseline normal BMI and stable weight during follow-up (Figure 3, Figure S2 and Table S5). 
Secondary analysis using lung function z-scores instead of absolute lung function showed 
similar results as the main analysis for all lung function parameters (Figure S3). Stratification by 
sex showed that FVC and FEV1 decline was steeper in men who gained weight than in their 
female counterparts, particularly in the obese category (Figures S4 and S5), but we there was no 
difference in regards to the FEV1/FVC ratio (Figure S6). All sensitivity analyses showed very 
similar results (Figures S7 to S12). However, the lung function differences between the 
reference category and some overweight/obese weight change profiles were attenuated when the 
analyses were restricted to participants who reported to being non-smokers at all examinations 
and when additionally adjusting for physical activity, educational level and any long-term 
limiting illness. 
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DISCUSSION 
In this population-based study we found that weight change over a twenty-year period was 
associated with the rate of lung function decline in adulthood. Specifically, we found that: (i) in 
participants with baseline normal BMI, overweight and obesity in young adulthood, moderate 
and high weight gain during follow-up were associated with accelerated FVC and FEV1 decline, 
(ii) in participants with obesity in young adulthood, weight loss during follow-up was associated 
with attenuated FVC and FEV1 decline, (iii) in underweight participants in young adulthood, 
stable weight during follow-up was associated with an attenuation of FVC and FEV1 decline, 
and (iv) we found no evidence of an association between weight change and FEV1/FVC ratio 
decline, with the exception of underweight participants with either stable weight or moderate 
weight gain both of whom exhibited accelerated FEV1/FVC ratio decline over follow-up.  
Interpretation  
Our findings that moderate and high weight gain accelerate FVC and FEV1 decline and that 
weight loss attenuates it are consistent with previous research in young adults.[3–10] This 
demonstrates how weight changes can affect lung function until late adulthood. Our approach of 
combining baseline BMI categories with weight change over time let us distinguish the effects 
of different weight change profiles on lung function throughout adult life. Two potential 
mechanisms have been proposed to explain the association of weight gain with accelerated lung 
function decline. First, weight gain can affect lung function through mechanical effects on 
lungs. Abdominal and thoracic fat mass are likely to reduce vital capacity by limiting the room 
for lung expansion during inspiration, in turn leading to expiratory flow limitation.[19] These 
mechanical effects may also explain the observed sex differences in relation to lung function 
decline, consistent with previous studies,[4,8,20] as men tend to accumulate more fat mass in 
the abdominal area than women.[21] Second, weight gain can impair lung function by 
inflammatory processes, as adipose tissue is a source of inflammatory mediators[22,23] that can 
damage lung tissue and reduce airway diameter.[24] Unfortunately, we did not have measures 
of chest compliance or markers of systemic inflammation related to obesity, and therefore we 
could not disentangle the mechanical effects of body mass on lung function from the 
inflammatory effects. 
There are some potential mechanisms that can explain the association between weight loss and 
attenuation of lung function decline in obese subjects. First, it is possible that weight loss 
reverses the mechanical effects of overweight/obesity on the respiratory system allowing the 
recovery of lung function. Second, weigh loss may relate to a reduction of inflammatory 
processes in the lung which in turn can help to attenuate lung function decline related to 
excessive weight. This hypothesis is supported by previous research showing that lung function 
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decline associated with air pollution, which likely affects lung function via inflammation, could 
be attenuated with improvement of air quality.[25] Third, weight loss may be accompanied by 
improvement of metabolic alterations related to excess body weight, such as insulin 
dysregulation, high fasting glucose levels, hyperlipidemia or systemic hypertension, that are 
also related to impaired lung function.[26,27] Fourth, the observed association between weight 
loss and attenuated lung function decline could be related to confounding by changes in lifestyle 
(e.g. increasing physical activity or changing diet) that can follow awareness of the harmful 
effects of overweight/obesity. Indeed, quitting smoking and becoming physically active in 
adulthood had been related to better lung function levels and/or attenuated lung function 
decline.[8,18,28,29] Although we accounted for changes in smoking status during follow-up, 
levels of physical activity and presence of long-term limiting illness that could be accompanied 
by metabolic alterations (hypertension, heart disease, diabetes, cancer or stroke) at ECRHS II in 
sensitivity analyses, we did not have information on physical activity or diet at baseline. Further 
studies with repeated measures of lifestyle factors and indicators of metabolic dysregulation 
associated with weight changes are needed to disentangle the mechanisms underlying the 
association of weight loss and attenuated lung function decline.  
We also found that stable weight during follow-up in individuals underweight in young 
adulthood was associated with attenuated FVC and FEV1 decline, while those with baseline 
underweight and moderate weight gain had a parallel FVC and FEV1 decline to individuals with 
baseline normal BMI in late adulthood. These findings contrast with results of a previous 
longitudinal study showing that increasing BMI in initially thin adults (aged 18-30) was 
associated with lung function improvement over ten years.[9] This inconsistency could be 
related to differences in the definition of weight gain (i.e. the use of BMI gain vs. of weight 
change) and to a different baseline age range. The relationship between weight change and lung 
function has received little attention in healthy underweight individuals, thus further research is 
needed to understand the effects of weight change in underweight individuals and their 
underlying mechanisms.  
In the present analysis, we did not observe statistically different FEV1/FVC ratio trajectories by 
weight change profiles, except for underweight subjects with either stable weight or moderate 
weight gain during follow-up, both of whom exhibited a faster FEV1/FVC decline over follow-
up. The observed associations in underweight subjects are in line with findings of one previous 
study in healthy adults [9] and allow us to hypothesize that underweight subjects could be more 
susceptible to the development of airflow limitation with aging. Also, the lack of association of 
weight gain with FEV1/FVC ratio in the present analysis is in line with previous studies 
showing that FEV1/FVC ratio is normal in overweight and obese individuals. [19] The lack of 
association of weight gain with FEV1/FVC ratio could be attributed to the fact that both FVC 
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and FEV1 declines were accelerated with weight gain, which could lead to a null net effect on 
the ratio of these two measures (as both denominator and numerator were equally affected). 
This pattern suggests that weight gain is likely to be related with a restrictive pattern, 
characterized by a reduction of lung volumes with no effect on airflow limitation. This 
hypothesis is supported by previous evidence showing that obesity is more likely to be 
associated with a restrictive ventilatory pattern than an obstructive one. [30]  
 
Strengths and limitations 
A strength of the current study is the long follow-up (up to twenty years) and the width of age 
distribution, covering early to late adulthood. The population-based nature of the ECRHS and 
broad geographical representation of participants (26 centres in 12 countries in Europe and 
Australia) supports external validity of our results. Finally, we had lung function measures at 
three time points, which allowed us to estimate lung function trajectories. 
A limitation of this study is the use of total body weight as the main exposure. Although total 
body weight has been largely used in epidemiological studies as a marker of overweight and 
obesity, it is limited by its inability to distinguish between fat and muscle mass, which vary with 
age and sex [31,32] and could have different effects on lung function, as previously shown in 
children.[33] Also, we defined weight change categories using only weight measures at baseline 
and last follow-up to capture ‘stable’ weight change patterns and facilitate the interpretability of 
our results. Of note, the correlation between individual weight change per year (taking into 
account three weight measurements) and the weight change variable used in our analysis was 
0.998, which justifies our approach. However, we recognise that our approach precludes us to 
determine how long it takes for a change in weight to affect lung function decline. Given the 
lack of standard references for weight change in adults, we categorized weight change based on 
a previous longitudinal study, [17] limiting the interpretation of our findings to our definition of 
‘stable weight’ (±0.25kg/year). However, results were very similar when repeating our analysis 
using a wider category for ‘stable weight’ (±0.50kg/year), suggesting that our findings are 
robust even with a less restrictive definition of ‘stable weight’. Our results may be also affected 
by selection bias as participants were more likely to be highly educated and less likely to be 
current-smokers or to be exposed to second hand smoke, than those lost to follow-up. Because 
these factors have been previously associated with lung function, our associations could be 
underestimates of the true associations in the general population. Although we accounted for a 
wide range of confounders, our results could be affected by potential residual confounding by, 
for example, dietary intake, which affects both body weight and lung function, as the available 
data on diet were limited to a small subset of the study sample at ECRHS II and III. Moreover, 
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the spirometers used for lung function assessment were changed in some centres, which could 
have led to systematic differences inherent in lung function measurement that may differ by age 
and height.[34] However when we adjusted our analysis for spirometer type and when we 
replicated the analyses using lung function values corrected for change in spirometer we 
obtained consistent results. Finally, we used three repeated measures of lung function from a 
sample aged 20-44 (mean age: 34.3; SD: 7.1) years at baseline and 39-67 (mean age: 54.3; SD: 
7.1) years at the last follow-up to estimate lung function trajectories throughout adulthood. 
However, few participants were aged around 20 years at baseline and around 67 years at the last 
follow-up, and in consequence the models had fewer observations at the age-ends than in 
between 30-60, where most of the observations were. 
Conclusion 
In conclusion, this prospective population-based study shows that moderate and high weight 
gain over a twenty-year period was associated with accelerated lung function decline in 
adulthood, while weight loss was related to its attenuation. Our findings together with existing 
literature, reinforce the public health message that overweight and obesity have deleterious 
effects on health, including respiratory health. However, the negative effects of overweight and 
obesity on lung function can be reversed by weight loss even later in adult life. Therefore, 
public health policies that promote healthy lifestyles and body weight may be important for 
maintaining good lung function in adult life. 
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Table 1. Characteristics of the study sample* 
 ECRHS I  ECRHS II  ECRHS III 
Characteristics 
n (%) or  
mean (SD) 
 n (%) or  
mean (SD) 
 n (%) or  
mean (SD) 
Symptomatic study arm  544 (14.8)  -  - 
Sex. Women 1,956 (53.3)  -  - 
Age in years  34.3 (7.1)  43.0 (7.0)  54.3 (7.1) 
Height in cm 170.6 (9.4)  170.3 (9.4)  169.4 (9.5) 
Weight in kg 69.5 (13.5)  74.0 (15.1)  77.9 (16.1) 
BMI       
Continuous, in kg/m2   23.8 (3.7)  25.4 (4.3)  27.1 (4.9) 
Underweight 453 (12.3)  222 (6.1)  119 (3.2) 
Normal weight 2,097 (57.1)  1,676 (45.8)  1,224 (33.3) 
Overweight 892 (24.3)  1,298 (35.5)  1,481 (40.3) 
Obese 231 (6.3)  461 (12.6)  849 (23.1) 
Smoking status      
Non-smoker 1,651 (45.0)  1,576 (42.9)  1,518 (41.3) 
Ex-smoker  818 (22.3)  1,119 (30.5)  1,500 (40.8) 
Current smoker 1,204 (32.8)  978 (26.6)  655 (17.8) 
Second-hand smoke exposure. Yes 1,939 (52.9)  1,321 (36.1)  680 (18.6) 
Current asthma**. Yes 378 (10.5)  491 (13.8)  570 (16.2) 
Age completed full time education       
<17 years 675 (21.5)  -  - 
17-20 years 1,205 (38.4)  -  - 
>20 years 1,256 (40.1)  -  - 
Physical activity. Active status†  -  1,363 (52.2)  - 
Any long-term limiting illness‡. Yes -  405 (17.1)  - 
Lung function       
FVC (mL) 4,516 (988)  4,354 (980)  3,964 (948) 
FEV1 (mL) 3,702 (798)  3,485 (790)  3006 (753) 
FEV1/FVC (%) 82.3 (6.9)  80.3 (6.5)  75.8 (6.5) 
Lung function (z-scores)§      
FVC z-score 0.01 (0.95)  0.02 (1.00)  -0.08 (0.94) 
FEV1 z-score -0.01 (1.06)  -0.03 (1.08)  -0.34 (1.04) 
FEV1/FVC z-score -0.06 (1.03)  -0.10 (1.00)  -0.48 (0.89) 
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**Current asthma was defined as having reported physician-diagnosed asthma and at least one of the following: asthma-like 
symptoms (wheeze, nocturnal chest tightness, attacks of breathlessness after activity/at rest/at night-time), asthma attacks, use of 
inhaled/oral medicines for breathing problems (in the last 12 months), or current use of inhalers, aerosols or tablets for asthma   
† Individuals were categorised as being active if they exercised with a frequency of two or more times a week and with a duration of 
about one hour a week or more 
‡The following illness were considered: hypertension, heart disease, diabetes, cancer or stroke. 
§ Lung function z-scores were derived using Global Lung Initiative 2012 equations.  
Abbreviations: BMI, body mass index; FEV1, volume expired in the first second; FVC, forced vital capacity; SD, standard deviation 
*Some variables had missing values. Number of missings for ECRHS I: 10 in second-hand smoke exposure, 78 in current asthma, 
and 537 in age completed full time education. Number of missings for ECRHS II: 18 in second-hand smoke exposure, 118 in 
current asthma, 1,062 in physical activity and 1,300 in any long-term limiting illness. Number of missings for ECRHS III: 14 in 
second-hand smoke exposure and 163 in current asthma  
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* Weight change profiles were defined combining BMI at baseline and weight change during follow-up. BMI categories at baseline: underweight: BMI<20 kg/m2; normal weight: 20 kg/m2 ≤ BMI< 25 kg/m2; 
overweight: 25 kg/m2 ≤ BMI < 30 kg/m2; obese: BMI ≥ 30 kg/m2.  Weight change was computed as the difference between weight measured at ECRHS III and ECRHS I divided by the total duration follow-up (in 
years). Weight change categories: weight loss: < -0.25 kg/year; stable: within ±0.25 kg/year; moderate weight gain: 0.25-1 kg/year; high weight gain: >1 kg/year.   
† Not analysed further because of small sample size 
Table 2. Descriptive statistics of weight change profiles 
Weight change profiles* n (%) Weight ECRHS I [kg] 
Median (P25; P75) 
Weight ECRHS III [kg] 
Median (P25; P75) 
Weight change during follow-up 
[kg/year] 
Median (P25; P75) 
Underweight 
Weight loss 2 (0.1) † 55.5 (54; 57) 48.5 (45; 52) -0.3 (-0.4; -0.3) 
Stable weight 167 (4.6) 53 (50; 56) 55 (51; 59) 0.1 (0; 0.2) 
Moderate weight gain 259 (7.1) 53 (50; 58) 65.3 (60; 70.4) 0.5 (0.4; 0.7) 
High weight gain 25 (0.7) † 52 (50; 57) 78 (74; 85) 1.2 (1.1; 1.5) 
Normal BMI 
Weight loss 38 (1) 63.5 (60; 74) 55 (52; 65) -0.4 (-0.4; -0.3) 
Stable weight 715 (19.5) 64 (59; 72) 65.8 (60; 74) 0.1 (0.0; 0.2) 
Moderate weight gain 1,164 (31.7) 65 (60; 72) 76 (70; 84) 0.5 (0.4; 0.7) 
High weight gain 180 (4.9) 66 (60; 72) 92.4 (86; 98) 1.2 (1.1; 1.4) 
Overweight 
Weight loss 52 (1.4) 80 (76; 87) 71 (66; 75.8) -0.4 (-0.6; -0.3) 
Stable weight 291 (7.9) 79 (73; 85) 80 (73; 86.8) 0.1 (-0.1; 0.2) 
Moderate weight gain 454 (12.4) 80 (73; 86) 90.9 (84; 97.1) 0.5 (0.4; 0.7) 
High weight gain 95 (2.6) 79 (70; 85) 103 (96.4; 113.9) 1.3 (1.1; 1.5) 
Obese 
Weight loss 46 (1.3) 95 (87; 105) 85 (72; 93) -0.6 (-0.9; -0.4) 
Stable weight 65 (1.8) 90 (85; 100) 92 (85; 101) 0.1 (-0.1; 0.1) 
Moderate weight gain 85 (2.3) 93 (87; 103) 105 (97.1; 114) 0.5 (0.4; 0.7) 
High weight gain 35 (1) 95 (85; 109) 125 (112; 135) 1.3 (1.1; 1.8) 
Overall  3,673 (100) 68 (59; 78) 76 (66; 87.3) 0.4 (0.1; 0.7) 
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LIST OF FIGURES 
Figure 1. Estimated trajectories of FVC (mL) decline, by weight change profiles 
Figure shows estimated FVC values and their correspondent 95% confidence intervals (95%CI). Models 
are adjusted for sex, height, age, age squared, smoking status, an interaction term between smoking status 
and age, current asthma and spirometer type. Reference category: normal BMI at baseline and stable 
weight during follow-up. All graphs are presented with a ‘jitter’ (0.05) to avoid overlap of confidence 
interval bars. 
Abbreviations: BMI, body mass index; FVC, forced vital capacity. 
Figure 2. Estimated trajectories of FEV1 (mL) decline, by weight change profiles 
Figure shows estimated FEV1 values and their correspondent 95% confidence intervals (95%CI). Models 
are adjusted for sex, height, age, age squared, smoking status, an interaction term between smoking status 
and age, current asthma and spirometer type. Reference category: normal BMI at baseline and stable 
weight during follow-up. All graphs are presented with a ‘jitter’ (0.05) to avoid overlap of confidence 
interval bars. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second. 
Figure 3. Estimated trajectories of FEV1/FVC (%) decline, by weight change profiles 
Figure shows estimated FEV1/FVC values and their correspondent 95% confidence intervals (95%CI). 
Models are adjusted for sex, height, age, age squared, smoking status, an interaction term between 
smoking status and age, current asthma and spirometer type. Reference category: normal BMI at baseline 
and stable weight during follow-up. All graphs are presented with a ‘jitter’ (0.05) to avoid overlap of 
confidence interval bars. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity. 
 
